GlaxoSmithKline Standalone June 2024 Net Sales at Rs 811.00 crore, up 9.89% Y-o-Y
August 05, 2024 / 13:49 IST
Reported Standalone quarterly numbers for GlaxoSmithKline Pharmaceuticals are:Net Sales at Rs 811.00 crore in June 2024 up 9.89% from Rs. 738.02 crore in June 2023.
Quarterly Net Profit at Rs. 181.65 crore in June 2024 up 39.11% from Rs. 130.58 crore in June 2023.
EBITDA stands at Rs. 265.27 crore in June 2024 up 48.99% from Rs. 178.05 crore in June 2023.
GlaxoSmithKline EPS has increased to Rs. 10.72 in June 2024 from Rs. 6.94 in June 2023.
| GlaxoSmithKline shares closed at 2,820.25 on August 02, 2024 (NSE) and has given 22.22% returns over the last 6 months and 100.73% over the last 12 months. |
| GlaxoSmithKline Pharmaceuticals | | Standalone Quarterly Results | in Rs. Cr. |
|
| Jun'24 | Mar'24 | Jun'23 | | Net Sales/Income from operations | 811.00 | 910.87 | 738.02 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 811.00 | 910.87 | 738.02 | | EXPENDITURE | | Consumption of Raw Materials | 133.33 | 192.29 | 145.47 | | Purchase of Traded Goods | 172.74 | 255.74 | 174.20 | | Increase/Decrease in Stocks | -13.26 | -98.90 | -44.38 | | Power & Fuel | -- | -- | -- | | Employees Cost | 151.28 | 172.83 | 165.00 | | Depreciation | 16.41 | 18.10 | 16.36 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 137.49 | 133.60 | 156.48 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | 213.01 | 237.21 | 124.89 | | Other Income | 35.85 | 29.87 | 36.80 | | P/L Before Int., Excpt. Items & Tax | 248.86 | 267.08 | 161.69 | | Interest | 0.37 | 0.77 | 0.28 | | P/L Before Exceptional Items & Tax | 248.49 | 266.31 | 161.41 | | Exceptional Items | -- | 2.40 | 17.30 | | P/L Before Tax | 248.49 | 268.71 | 178.71 | | Tax | 66.84 | 75.63 | 48.13 | | P/L After Tax from Ordinary Activities | 181.65 | 193.08 | 130.58 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | 181.65 | 193.08 | 130.58 | | Equity Share Capital | 169.41 | 169.41 | 169.41 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | 10.72 | 11.29 | 6.94 | | Diluted EPS | 10.72 | 11.39 | 7.71 | | EPS After Extra Ordinary | | Basic EPS | 10.72 | 11.29 | 6.94 | | Diluted EPS | 10.72 | 11.39 | 7.71 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
